Literature DB >> 18171295

Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy.

Peter W Hunt1, Jason Brenchley, Elizabeth Sinclair, Joseph M McCune, Michelle Roland, Kimberly Page-Shafer, Priscilla Hsue, Brinda Emu, Melissa Krone, Harry Lampiris, Daniel Douek, Jeffrey N Martin, Steven G Deeks.   

Abstract

BACKGROUND: Although untreated human immunodeficiency virus (HIV)-infected patients maintaining undetectable plasma HIV RNA levels (elite controllers) have high HIV-specific immune responses, it is unclear whether they experience abnormal levels of T cell activation, potentially contributing to immunodeficiency.
METHODS: We compared percentages of activated (CD38(+)HLA-DR(+)) T cells between 30 elite controllers, 47 HIV-uninfected individuals, 187 HIV-infected individuals with undetectable viremia receiving antiretroviral therapy (antiretroviral therapy suppressed), and 66 untreated HIV-infected individuals with detectable viremia. Because mucosal translocation of bacterial products may contribute to T cell activation in HIV infection, we also measured plasma lipopolysaccharide (LPS) levels.
RESULTS: Although the median CD4(+) cell count in controllers was 727 cells/mm(3), 3 (10%) had CD4(+) cell counts <350 cells/mm(3) and 2 (7%) had acquired immunodeficiency syndrome. Controllers had higher CD4(+) and CD8(+) cell activation levels (P < .001 for both) than HIV-negative subjects and higher CD8(+) cell activation levels than the antiretroviral therapy suppressed (P = .048). In controllers, higher CD4(+) and CD8(+) T cell activation was associated with lower CD4(+) cell counts (P = .009 and P = .047). Controllers had higher LPS levels than HIV-negative subjects (P < .001), and in controllers higher LPS level was associated with higher CD8(+) T cell activation (P = .039).
CONCLUSION: HIV controllers have abnormally high T cell activation levels, which may contribute to progressive CD4(+) T cell loss even without measurable viremia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18171295      PMCID: PMC3466592          DOI: 10.1086/524143

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  47 in total

1.  Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.

Authors:  J W Mellors; A Muñoz; J V Giorgi; J B Margolick; C J Tassoni; P Gupta; L A Kingsley; J A Todd; A J Saah; R Detels; J P Phair; C R Rinaldo
Journal:  Ann Intern Med       Date:  1997-06-15       Impact factor: 25.391

2.  Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia.

Authors:  E S Rosenberg; J M Billingsley; A M Caliendo; S L Boswell; P E Sax; S A Kalams; B D Walker
Journal:  Science       Date:  1997-11-21       Impact factor: 47.728

3.  Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression.

Authors:  Z Liu; W G Cumberland; L E Hultin; H E Prince; R Detels; J V Giorgi
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1997-10-01

4.  Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV-1 infection.

Authors:  J V Giorgi; M A Majchrowicz; T D Johnson; P Hultin; J Matud; R Detels
Journal:  AIDS       Date:  1998-10-01       Impact factor: 4.177

5.  CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency.

Authors:  Z Liu; W G Cumberland; L E Hultin; A H Kaplan; R Detels; J V Giorgi
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998-08-01

6.  Associations between HLA frequencies and pathogenic features of human immunodeficiency virus type 1 infection in seroconverters from the Amsterdam cohort of homosexual men.

Authors:  M R Klein; I P Keet; J D'Amaro; R J Bende; A Hekman; B Mesman; M Koot; L P de Waal; R A Coutinho; F Miedema
Journal:  J Infect Dis       Date:  1994-06       Impact factor: 5.226

7.  Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection.

Authors:  R A Kaslow; M Carrington; R Apple; L Park; A Muñoz; A J Saah; J J Goedert; C Winkler; S J O'Brien; C Rinaldo; R Detels; W Blattner; J Phair; H Erlich; D L Mann
Journal:  Nat Med       Date:  1996-04       Impact factor: 53.440

8.  AIDS enteropathy: occult enteric infections and duodenal mucosal alterations in chronic diarrhea.

Authors:  J K Greenson; P C Belitsos; J H Yardley; J G Bartlett
Journal:  Ann Intern Med       Date:  1991-03-01       Impact factor: 25.391

9.  Natural killer cell function is well preserved in asymptomatic human immunodeficiency virus type 2 (HIV-2) infection but similar to that of HIV-1 infection when CD4 T-cell counts fall.

Authors:  Samuel Victor Nuvor; Marianne van der Sande; Sarah Rowland-Jones; Hilton Whittle; Assan Jaye
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

10.  CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract.

Authors:  Jason M Brenchley; Timothy W Schacker; Laura E Ruff; David A Price; Jodie H Taylor; Gregory J Beilman; Phuong L Nguyen; Alexander Khoruts; Matthew Larson; Ashley T Haase; Daniel C Douek
Journal:  J Exp Med       Date:  2004-09-13       Impact factor: 14.307

View more
  349 in total

1.  HIV-1 continues to replicate and evolve in patients with natural control of HIV infection.

Authors:  Helene Mens; Mary Kearney; Ann Wiegand; Wei Shao; Kristian Schønning; Jan Gerstoft; Niels Obel; Frank Maldarelli; John W Mellors; Thomas Benfield; John M Coffin
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

2.  Dissociation of CD154 and cytokine expression patterns in CD38+ CD4+ memory T cells in chronic HIV-1 infection.

Authors:  Enrique Espinosa; Christopher E Ormsby; Gustavo Reyes-Terán; Robert Asaad; Scott F Sieg; Michael M Lederman
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12       Impact factor: 3.731

Review 3.  Management of the metabolic effects of HIV and HIV drugs.

Authors:  Todd T Brown; Marshall J Glesby
Journal:  Nat Rev Endocrinol       Date:  2011-09-20       Impact factor: 43.330

4.  On high alert.

Authors:  Emma Marris
Journal:  Nature       Date:  2010-07-15       Impact factor: 49.962

5.  Early immune senescence in HIV disease.

Authors:  Seema Desai; Alan Landay
Journal:  Curr HIV/AIDS Rep       Date:  2010-02       Impact factor: 5.071

6.  Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus.

Authors:  Karen A O'Connell; Timothy P Brennan; Justin R Bailey; Stuart C Ray; Robert F Siliciano; Joel N Blankson
Journal:  J Virol       Date:  2010-05-05       Impact factor: 5.103

Review 7.  Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society-Lancet Commission.

Authors:  Linda-Gail Bekker; George Alleyne; Stefan Baral; Javier Cepeda; Demetre Daskalakis; David Dowdy; Mark Dybul; Serge Eholie; Kene Esom; Geoff Garnett; Anna Grimsrud; James Hakim; Diane Havlir; Michael T Isbell; Leigh Johnson; Adeeba Kamarulzaman; Parastu Kasaie; Michel Kazatchkine; Nduku Kilonzo; Michael Klag; Marina Klein; Sharon R Lewin; Chewe Luo; Keletso Makofane; Natasha K Martin; Kenneth Mayer; Gregorio Millett; Ntobeko Ntusi; Loyce Pace; Carey Pike; Peter Piot; Anton Pozniak; Thomas C Quinn; Jurgen Rockstroh; Jirair Ratevosian; Owen Ryan; Serra Sippel; Bruno Spire; Agnes Soucat; Ann Starrs; Steffanie A Strathdee; Nicholas Thomson; Stefano Vella; Mauro Schechter; Peter Vickerman; Brian Weir; Chris Beyrer
Journal:  Lancet       Date:  2018-07-20       Impact factor: 79.321

8.  HIV RNA levels in plasma and cervical-vaginal lavage fluid in elite controllers and HAART recipients.

Authors:  Alan Landay; Elizabeth T Golub; Seema Desai; Jinbing Zhang; Val Winkelman; Kathryn Anastos; Helen Durkin; Mary Young; Maria C Villacres; Ruth M Greenblatt; Philip J Norris; Michael P Busch
Journal:  AIDS       Date:  2014-03-13       Impact factor: 4.177

9.  Development of neurological disease is associated with increased immune activation in simian immunodeficiency virus-infected macaques.

Authors:  Que Dang; Sonya Whitted; Robert M Goeken; Jason M Brenchley; Kenta Matsuda; Charles R Brown; Bernard A P Lafont; Matthew F Starost; Ranjini Iyengar; Ronald J Plishka; Alicia Buckler-White; Vanessa M Hirsch
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

10.  Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers.

Authors:  Florencia Pereyra; Janet Lo; Virginia A Triant; Jeffrey Wei; Maria J Buzon; Kathleen V Fitch; Janice Hwang; Jennifer H Campbell; Tricia H Burdo; Kenneth C Williams; Suhny Abbara; Steven K Grinspoon
Journal:  AIDS       Date:  2012-11-28       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.